Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 141 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015', provides an overview of the Transitional Cell Cancer (Urothelial Cell Cancer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Transitional Cell Cancer (Urothelial Cell Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Transitional Cell Cancer (Urothelial Cell Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of table 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Transitional Cell Cancer (Urothelial Cell Cancer) Overview 8
Therapeutics Development 9
Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Overview 9
Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis 10
Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics under Development by Companies 11
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Transitional Cell Cancer (Urothelial Cell Cancer) - Products under Development by Companies 16
Transitional Cell Cancer (Urothelial Cell Cancer) - Companies Involved in Therapeutics Development 18
Altor BioScience Corporation 18
Astellas Pharma Inc. 19
AstraZeneca PLC 20
Boston Biomedical, Inc. 21
Corcept Therapeutics Incorporated 22
Eli Lilly and Company 23
Exelixis, Inc. 24
GlaxoSmithKline plc 25
Innate Therapeutics Limited 26
Merck & Co., Inc. 27
Merck KGaA 28
Mirati Therapeutics Inc. 29
Novartis AG 30
Pfizer Inc. 31
Sanofi 32
Sumitomo Dainippon Pharma Co., Ltd. 33
Teva Pharmaceutical Industries Limited 34
Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ACP-196 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AGS-15E - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ALT-801 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
amrubicin hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASG-15ME - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
avelumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AZD-4547 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BBI-503 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
buparlisib hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
cabazitaxel - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cabozantinib s-malate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CEP-11981 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
enfortumab vedotin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
mifepristone - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MIS-416 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
mocetinostat - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
palbociclib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pembrolizumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ramucirumab - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SAR-408701 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
SNX-5422 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
trametinib dimethyl sulfoxide - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Transitional Cell Cancer (Urothelial Cell Cancer) - Recent Pipeline Updates 98
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects 135
Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products 137
Transitional Cell Cancer (Urothelial Cell Cancer) - Product Development Milestones 138
Featured News & Press Releases 138
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 138
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 140
Disclaimer 141

List of Tables
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H1 2015 9
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Altor BioScience Corporation, H1 2015 18
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Astellas Pharma Inc., H1 2015 19
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by AstraZeneca PLC, H1 2015 20
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Boston Biomedical, Inc., H1 2015 21
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Corcept Therapeutics Incorporated, H1 2015 22
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Eli Lilly and Company, H1 2015 23
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Exelixis, Inc., H1 2015 24
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by GlaxoSmithKline plc, H1 2015 25
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Innate Therapeutics Limited, H1 2015 26
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck & Co., Inc., H1 2015 27
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck KGaA, H1 2015 28
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Mirati Therapeutics Inc., H1 2015 29
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Novartis AG, H1 2015 30
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Pfizer Inc., H1 2015 31
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sanofi, H1 2015 32
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 33
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 34
Assessment by Monotherapy Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 40
Number of Products by Stage and Route of Administration, H1 2015 42
Number of Products by Stage and Molecule Type, H1 2015 44
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Recent Pipeline Updates, H1 2015 98
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects, H1 2015 135
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects (Contd..1), H1 2015 136
Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products, H1 2015 137